Wire · opportunities
Scholar Rock gets first FDA nod for rare muscle-wasting disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 September 2026 · Fusion42 review
The U.S. FDA has approved Scholar Rock's injectable therapy Isembyld for treating spinal muscular atrophy, marking the company's first regulatory approval with expected strong market potential.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 12 Sep 2026 and 14 Sep 2026.
◆ ◆ The Wire takeaway
You should prepare for competition with Biogen, Novartis, and Roche as Scholar Rock enters the spinal muscular atrophy treatment market with FDA backing. Manufacturing and sales strategies will be key to capturing patient segments where existing therapies dominate.
◆ Coverage
9 sources · first reported 12 Sep 2026 · latest 14 Sep 2026
◆ Related on Wire
◆ Topics